1 December 2020 - 2 December 2020
Reimbursement Systems for Pharmaceuticals in Europe
LEVEL - Intermediate
TRACK - Health Policy & Regulatory
LENGTH: 8 Hour | Course runs 2 consecutive days, 4 hours/day
Tuesday, 1 December | 4 Hours of content plus 30 minute break:
08:00-12:30 Eastern Standard Time (EST)
13:00-17:30 Greenwich Mean Time (GMT)
14:00-18:30 Central European Time (CET)
Wednesday, 2 December | 4 Hours of content plus 30 minute break:
08:00-12:30 Eastern Standard Time (EST)
13:00-17:30 Greenwich Mean Time (GMT)
14:00-18:30 Central European Time (CET)
DAILY SCHEDULE:
Class Time: 2 hours
Break: 30 minutes
Class Time: 2 hours
Click for time zone conversion
DESCRIPTION
Unlike marketing authorization for pharmaceuticals, mainly regulated at the European level by EMA, pricing and reimbursement decisions in Europe are managed by individual member states. Health care services are generally covered by a single public health insurer operating under the Ministry of Health supervision. As a monopoly buyer, this situation provides a leading position for the public health insurer to set reimbursement conditions. Therefore, based on each country’s set of regulations, processes, and values, wide variations exist in pricing and reimbursement decisions of pharmaceuticals. Using up-to-date governmental regulation sources and the ISPOR Global Health Care Systems Roadmap, this course will discuss health technology decision-making processes for reimbursement decisions for pharmaceuticals in France, Germany, Hungary, Italy, Poland, Spain, Sweden, and the UK. The course will describe these reimbursement systems, as well as compare, and bring into contrast their key characteristics. This course is designed for individuals with intermediate experience within a single healthcare system wishing to broaden their appreciation of other reimbursement systems.
FACULTY MEMBERS
Mondher Toumi, MD, MSc, PhD
Professor, Public Health, Aix Marseille University
Marseille, France